Deutsche Bank downgraded Tecan (TCHBF) to Hold from Buy with a price target of CHF 225, down from CHF 298. With 7%-8% of sales exposed to National Institutes of Health funding, Tecan appears particularly vulnerable to spending cuts, the analyst tells investors in a research note.